Description 
INFINITY pooled participant‑level data from three phase‑3 finerenone trials (FIDELIO‑DKD, FIGARO‑DKD, FIND‑CKD), assembling over 14,500 patients with a median follow‑up of about three years to evaluate long‑term kidney and cardiovascular protection. Finerenone lowered the risk of kidney failure or major sustained eGFR decline by 24% and reduced kidney failure alone by 15% versus placebo, outcomes that translate into fewer patients progressing to dialysis or transplantation. Cardiovascular benefits paralleled renal protection: a 20% reduction in heart‑failure hospitalization or cardiovascular death, with accompanying decreases in all‑cause mortality and need for dialysis or transplant. Benefits were consistent across diabetic and non‑diabetic CKD, across a range of eGFR and albuminuria levels, and irrespective of SGLT2‑inhibitor use, supporting broad applicability as an add‑on to RAS and SGLT2 therapy when albuminuria persists. Presented at ERA Congress 2026 and published in The Lancet, INFINITY supplies large‑scale, long‑term evidence that finerenone delivers dual organ protection—directly informing guideline recommendations and clinical practice, including in high‑burden settings.